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The Presence of COPD Does Not Influence Clinical Outcomes in Hospitalized Patients with Community-Acquired Pneumonia
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Abstract
Introduction: Community acquired pneumonia (CAP) is a leading cause of death worldwide.
Chronic obstructive pulmonary disease (COPD) is a well-established risk factor for development
of CAP. What is not as clear is the impact of COPD on the outcomes of patients with CAP. In this
study, we compared the outcomes of CAP in COPD and non-COPD patients.
Methods: This was a retrospective cohort study. We conducted an analysis of the CommunityAcquired Pneumonia Organization (CAPO) international cohort study database, which includes
patients with CAP admitted to several hospitals throughout the world. Patients were categorized
into two groups based on the status of COPD: COPD positive or negative. Outcomes were time
to clinical stability, length of hospital stay, and in-hospital mortality. Regression models were used
to assess the independent effect of COPD on the outcomes.
Results: This study included 7,325 patients. Of these, 1,869 (25.5%) had COPD. Patients with
COPD had higher severity of illness (pneumonia severity index class V: 15% vs 9%; P <0.001).
Accelerated failure time models with adjustment for co-variates showed no significant difference
in the probability of clinical stability (P = 0.451) and of discharge (P = 0.232) in COPD vs. nonCOPD patients. There was no difference in the crude in-hospital mortality between COPD and
non-COPD patients (9% vs 9%; P = 0.37).
Conclusion: Our study results show that COPD should not be considered a risk factor for poor
outcomes in hospitalized patients with CAP.

1

Introduction

Community acquired pneumonia (CAP) is a major cause of death.
In 2015, lower respiratory infections were estimated to be the
third leading cause of death globally. 1 The outcomes of this condition are directly related to factors associated with host, causal
agent, and conditions of diagnosis and treatment. The presence
of comorbidities is the most important factor linked to poorer outcomes. 2
Chronic obstructive pulmonary disease (COPD) is a condition
characterized by persistent airflow limitation and inflammation.
It is generally progressive and associated with chronically increased inflammatory response in the airways and lungs as a consequence of exposure to noxious particles or gases. 3 Worldwide,
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approximately 210 million people have COPD, which is considered the fourth leading cause of mortality resulting in approximately 7.8% of all deaths. 4 The incidence of CAP in subjects with
COPD is estimated to be 22.4 cases per 1,000 people with COPD
per year. 5
The presence of COPD as a comorbidity that affects mortality in
CAP is controversial. Some studies have found an association
with increased mortality, whereas others show no relationship
with COPD and poorer outcomes. 6 Luna et al. observed a mortality rate of 4.6% for CAP in individuals with no comorbidities
and 4% when associated with COPD. In this case, COPD was not
an independent factor associated with mortality. 2 A case-control
study from Switzerland observed lower in-hospital mortality and
a lower rate of complications when COPD was present. 7 Nonetheless, Torres et al. reported that asthma, smoking, chronic cardiovascular disease, diabetes and COPD increase the risk for pneumococcal disease (CAP and invasive pneumococcal disease), and
have a detrimental effect on outcomes. 8 In a study on elderly
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patients with CAP, COPD and dementia were considered independent risk factors for admission. 9 In a different study, the most
important factors contributing to higher mortality in patients with
COPD and CAP admitted to the intensive care unit (ICU) were the
presence of bilateral lung infiltrates and prolonged mechanical
ventilation, while systemic corticosteroid use and shorter length
of ICU stay seemed to be protective against a fatal outcome. 10
Disease severity is also independently associated with worse outcomes, increasing mortality and complication rates. 11 In the long
term follow-up, taking into account a 5-year period after the acute
event, COPD, cardiovascular disease and malignancy were the
leading causes of death. 12
Due to controversy in the literature, we conducted a study to test
the hypothesis that COPD is a risk factor for worse outcomes in
patients with CAP.

2
2.1

Methods
Study Design

This was a retrospective cohort study. We conducted an analysis of the Community-Acquired Pneumonia Organization (CAPO)
international cohort study database, which is formed by a collaboration of investigators throughout the world. Investigators fill out
a case report form for each case. Subsequently the data is transferred online to a HIPAA-compliant database hosted by the CAPO
study-coordinating center located at the University of Louisville in
Louisville, KY, USA. Research associates at the coordinating center validate the cases by ensuring data quality and integrity.
Our study included adult patients who required hospitalization
for CAP from April 27, 2000 to March 13, 2016. Hospitalizations
were from Europe, Latin American, USA, and Canada. Enrollment
criteria included age ≥18 years-old and the diagnosis of CAP.
2.2

Study Definitions

CAP was defined as a new pulmonary infiltrate plus at least one
of the following: new or worsening cough, fever (T > 37.8°C or
> 100°F) or hypothermia (<35.6°C or <96°F), increased white
cell count, left shift, or decreased white cell count. For the purpose of this study, "community-acquired" means the patient must
not have been hospitalized within the 2 weeks prior to the current hospitalization. Patient was defined as having COPD if the
presence of COPD was documented in the medical record. The
availability of pulmonary function test was not a requirement for
the diagnosis of COPD.
Time to clinical stability was defined as the first day the patient
fulfilled all four criteria: cough improving, afebrile for at least 8
hours, white blood cell improving or normal, and adequate oral
intake and absorption.
2.3

Measurements

Outcomes were time to clinical stability, length of hospital stay,
and in-hospital mortality. We obtained the following variables: demographics, physiological variables (e.g. temperature), need for mechanical ventilation, need for ICU admission,

co-morbidities, smoking status, pneumonia severity index (PSI)
class, 13 receipt of home infusion therapy, receipt of home wound
care, receipt of chronic dialysis within past 30 days, whether the
patient was hospitalized >2 days in the past 90 days, receipt of
intravenous antibiotics therapy in the past 90 days, and whether
the patient is a nursing home resident.
2.4

Statistical Methods

Descriptive statistics were performed on these hospitalizations.
Categorical variables were reported using frequency and percent.
Chi-Square tests were performed to compare patients with COPD
and patients without COPD for each categorical variable of interest. Continuous variables were reported using median and
interquartile range (IQR). Wilcoxon Rank Sum tests were performed to compare patients with COPD and patients without
COPD for each continuous variable of interest.
Kaplan Meier charts were used to compare time-to-event outcomes between patients with COPD and patients without COPD.
Log-rank tests were performed. Logistic regression was performed to find a model of best-fit predicting in-hospital mortality.
Variables used as predictors in the regression model were presence of COPD controlled by direct admission to the ICU, hospital
region, and PSI risk class.
Accelerated failure time (AFT) models were created using the lognormal distribution for time to clinical stability and length of stay
among patients with and without COPD. Variables that were controlled for each model were PSI risk class, hospital region, and
direct admission to the ICU. These models were made under the
assumption that "risk" for clinical stability and hospital discharge
change over time. Statistical significance was determined by a
P-value of less than 0.05. We used R software version 3.2.3. for
statistical analysis. 14

3
3.1

Results
Patient Characteristics

A total of 7,325 patients were included in the analysis. Of these,
1,869 (25.5%) had COPD. Patients with COPD were older (median age in years [IQR]: 75 [17] vs 65 [33]; P <0.001), had more
direct admissions to the ICU (12% vs 10%; P = 0.004), required
more ventilator support (22% vs 12%; P <0.001), and had higher
severity of illness (PSI class V: 15% vs 9%; P <0.001) (see Table 1). Patients with COPD who required mechanical ventilation
(168 [22%]) were supported predominantly through noninvasive
ventilation (123 out of 168 [73%]). Conversely, of non-COPD
patients who required mechanical ventilation (296 [12%]), half
(149 [50%]) were supported through noninvasive ventilation.
3.2

Outcomes

The median length of stay was 8 (interquartile range [IR]: 5.13)
days for patients with COPD vs 7 (IR: 5,12) days for patients without COPD. Log-rank test showed patients with COPD had lower
probability of discharge over time (P < 0.001) (see Figure 1).
Time to clinical stability was similar in patients with COPD (4
days; IR: 3,8) vs patients without COPD (4 days; IR: 3,8). Log-
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Table 1 Characteristics of the patients.

COPD

Non-COPD

P-value

Age, median (IQR)
Gender (male), n (%)
Altered mental status at admission, n (%)
Oxygen saturation (%), median (IQR)
SBP (mmHg), median (IQR)
Temperature (Celsius), median (IQR)
Directly admitted to ICU, n (%)
Transferred to ICU, n (%)

75 (17)
1328 (71)
248 (14)
92 (7)
130 (35)
37.2 (1.6)
230 (12)
49 (4)

65 (33)
3073 (56)
754 (14)
94 (7)
123 (30)
37.8 (1.6)
540 (10)
140 (4)

<0.001
<0.001
0.639
<0.001
<0.001
<0.001
0.004
0.38

Need for ventilator support day 0, n (%)
Invasive mechanical ventilation, n (%)
Non-invasive mechanical ventilation, n (%)

168 (22)
45 (27)
123 (73)

296 (12)
147 (50)
149 (50)

<0.001
<0.001
<0.001

Alcoholic, n (%)
Cerebrovascular disease, n (%)
Diabetes, n (%)
HIV, n (%)
Liver disease, n (%)
Neoplastic Disease within the past year, n (%)
Renal disease, n (%)
Chronic renal failure, n (%)
BUN in mg/dL, Median (IQR)
Serum glucose mg/dl, Median (IQR)
Hematocrit (%), Median (IQR)
Serum sodium (mEq/L), Median (IQR)
Mortality at Discharge, n (%)

31 (4)
290 (16)
377 (20)
40 (2)
95 (5)
226 (12)
225 (12)
241 (13)
35.5 (35)
125 (57)
39 (8)
137 (6)
175 (9)

106 (4)
762 (14)
980 (18)
349 (6)
322 (6)
551 (10)
548 (10)
480 (9)
31 (32)
119 (47)
38 (7.1)
136 (5)
472 (9)

0.918
0.1
0.035
<0.001
0.203
0.017
0.016
<0.001
<0.001
<0.001
<0.001
<0.001
0.37

Smoking status
Current Smoker, n (%)
History of smoking, n (%)
Non-smoking history, n (%)

272 (24)
569 (51)
279 (25)

733 (20)
909 (25)
2061 (56)

0.001
<0.001
<0.001

Chronic dialysis within past 30 days, n (%)
Risk Class I*, n (%)
Risk Class II*, n (%)
Risk Class III*, n (%)
Risk Class IV*, n (%)
Risk Class V*, n (%)
Home infusion therapy, n (%)
Home wound care, n (%)
Hospitalized >2 days in the past 90 days, n (%)
IV antibiotics therapy in the past 90 days, n (%)
Nursing home resident, n (%)

6 (1)
50 (3)
319 (17)
533 (29)
685 (37)
281 (15)
7 (1)
6 (1)
75 (10)
60 (8)
118 (6)

11 (0)
995 (18)
1180 (22)
1124 (21)
1646 (30)
508 (9)
27 (1)
24 (1)
164 (6)
110 (4)
295 (5)

0.252
<0.001
<0.001
<0.001
<0.001
<0.001
0.84
0.829
0.003
<0.001
0.147

*Risk class of pneumonia severity index. 13

rank test showed that time to clinical stability curves were not
significantly different (P = 0.105) (see Figure 2). There was no
difference in the crude in-hospital mortality between COPD and
non-COPD patients (9% vs 9%; P = 0.37). Additionally, there was
no significant difference in the adjusted risk of in-hospital mortality in COPD patients (RR: 0.849; 95% CI: 0.698 - 1.032; P = 0.1)
(see Table 2).
Accelerated failure time models with adjustment for co-variates
showed no significant difference in the probability of clinical stability (P = 0.451) and of discharge (P = 0.232) (see Figures 3
and 4).
3.3

4

Outcomes

Discussion

In patients with CAP, those with COPD were older, presented with
higher severity of illness, had more direct admissions to the ICU,
and required more mechanical ventilator support. Despite these
findings, they had similar unadjusted and adjusted in-hospital
mortality and time to clinical stability. COPD patients had higher
length of hospital stay. However, the difference was no longer
significant after adjustment for co-variates. The literature is consistent in showing that COPD is a risk factor for CAP, 5,9 and that
this risk increases with the severity of the COPD. 8 What is not as
clear is the impact of COPD on the outcomes of patients with CAP.

Jiang et al. observed more frequent ICU admissions and need
for mechanical ventilation in the COPD group; however, COPD
was not associated with a higher mortality rate. 6 Similar results
were found by Liapikou et al. and Dusemund et al. where inhospital mortality was similar for both groups. 7,15 On the other
hand, in an observational study of 710 in which all patients underwent spirometry, COPD was independently associated with an
increased risk of 30-day mortality (odds ratio = 2.62 [95% CI:
1.08-6.39]). 16
In our study, patients with COPD were older and had more comorbidities such as decompensated heart failure, renal disease,
and diabetes. Despite that, mortality rates did not differ between
groups. The finding of patients with more co-morbidities not having worse outcomes is counterintuitive. We have four hypothetical reasons that may explain our findings. First, patients with
COPD often receive systemic corticosteroids prior to and during
hospitalization with respiratory failure. Systemic corticosteroids
have been shown to be beneficial in CAP. 17 The benefit of systemic corticosteroids is particularly pronounced in patients with
severe CAP where a reduction in mortality by 61% was found in
a meta-analysis. 18 It can be speculated that the outpatient or inpatient use of corticosteroids for the management of COPD may
unintentionally improve CAP outcomes in these patients. Second, the chronic lung inflammation in COPD could paradoxically
have a protective effect in these patients. In this light, our group
ULJRI Vol 1,(3) 2017
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Fig. 1 Kaplan-Meier curves and log-rank test comparing probability of hospital discharge between COPD and non-COPD patients.

Fig. 2 Kaplan-Meier curves and log-rank test comparing time to clinical stability between COPD and non-COPD patients.

performed a prospective observational study in 40 hospitalized
patients with CAP with the goal of characterizing their inflammatory response. Patients with severe CAP had higher levels of
inflammatory cytokines in the blood but lower levels of inflammatory cytokines in the sputum as compared with patients with nonsevere CAP. 19 The presence of chronic local inflammation could
have a protective effect against pathogen growth in the lung although this is hypothetical and one could also argue that chronic
lung inflammation may lead to immune-senescence with detrimental effects. Third, perhaps the diagnosis of COPD prompts
physicians to take a more proactive approach in this group of patients with CAP. This proactive approach could include measures
such as closer monitoring of the respiratory status, earlier ICU admission, earlier use of non-invasive ventilation for those with hypercapnic respiratory failure, and a more thoughtful selection of
the antimicrobial regimen. Our study showed that patients with
COPD were more often directly admitted to the ICU, which could
reflect their higher severity of illness but also that physicians were
more cautious with this group of patients. Fourth, it is possible
that COPD patients were misdiagnosed with CAP when they ac-

tually had COPD exacerbations. The diagnosis of CAP in COPD
patients can be challenging, especially with a high frequency of
previously existing radiographic abnormalities, which could be
misleading to the clinician. As an example, a study showed that
the agreement among radiologists for the diagnosis of pneumonia on the chest radiograph is only moderate (kappa = 0.53).
In the presence of COPD, the agreement is even lower (kappa =
0.20). 20 Additionally, most COPD exacerbations are triggered by
an upper respiratory tract infection, 21 the symptoms of which can
be similar to those of a pneumonia.
We recognize a number of limitations in our study. The main
limitation is that the diagnosis of COPD was based on a history
of COPD as outlined in the medical record. These diagnoses
therefore could have self-reported by patients (which was most
common), based on clinical suspicion, or based on spirometry. It
should be noted that a self-reported diagnosis of COPD is highly
predictive of spirometry-confirmed COPD but the absence of a
self-reported diagnosis of COPD does not substantially decrease
the likelihood of spirometry-confirmed COPD. For example, in an
accuracy study of 309 patients, a self-reported history of chronic
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Table 2 Multiple logistic regression assessing the effect of variables on in-patient mortality.

History of COPD
Direct ICU admission
Region
Europe
Latin America
Risk Class*
II
III
IV
V

Risk Ratio (95% CI)

P value

0.849 (0.698-1.032)
3.047 (2.442-3.801)

0.1
<0.001

0.92 (0.735-1.153)
1.788 (1.41-2.266)

0.471
<0.001

1.823 (1.093-3.042)
3.26 (2.013-5.279)
7.555 (4.793-11.908)
19.15 (11.945-30.699)

0.021
<0.001
<0.001
<0.001

*Risk class of pneumonia severity index. 13

Fig. 3 Accelerated failure time model comparing adjusted probability of discharge between COPD and non-COPD patients (dotted lines represent
95% confidence interval).

obstructive airway disease had an adjusted positive likelihood ratio of 7.3 for the diagnosis of spirometry-confirmed COPD. On
the other hand, the absence of self-reported history of chronic obstructive airway disease had an adjusted negative likelihood ratio
of 0.5 for spirometry-confirmed COPD. 22 Our study is thus susceptible to misclassification bias, which would be non-differential
and bias the effect of COPD on outcomes towards the null. Additionally, the severity of COPD is directly related to worse outcomes including mortality. 11 Severity of COPD could not be assessed in the present study because data related to pulmonary
function tests and COPD staging were not available for the majority of the patients. Another limitation is that we do not have
information on systemic and inhaled corticosteroid use, or prior
outpatient antibiotic use. Finally, we do provide information on
long-term outcomes. Our study also has a number of strengths
including a large sample size, a worldwide patient population,
which increases the external validity of the study, and the collection of several clinical and physiological variables, which allowed
for a comprehensive description of our patient population and
the ability to adjust for severity of illness in the regression analyses. Future research could include studies with a cohort design in
which COPD is established by pulmonary function tests and the
impact of COPD on both short-term and long-term outcomes are
assessed. Additionally, the impact of the severity of COPD on the
outcomes of CAP should be evaluated. A better characterization

of the effect of pharmacological therapies for COPD on outcomes
of CAP is needed. For instance, what is the impact of COPD on
the outcomes of CAP after adjustment for the use of systemic corticosteroid? Is the use of inhaled corticosteroid during treatment
of CAP detrimental? Interestingly, a systematic review that included 43 randomized clinical trials (over 30,000 patients) found
that inhaled corticosteroids increase the risk of pneumonia and
hospitalizations in patients with COPD but do not increase the
all-cause mortality in these patients. 23 In summary, our study results show that in patients with CAP, those with COPD are sicker
as assessed by severity of illness and co-morbidities. Yet these
patients do not have worse short-term outcomes. Our findings
are in line with the PSI, a clinical prediction rule to risk stratify
patients with CAP that was initially prospectively validated in a
cohort of over 2,000 patients with CAP. COPD is not one of the
co-existing conditions that are part of this risk score. 13 We conclude that COPD should not be considered a risk factor for poor
outcomes in hospitalized patients with CAP.
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